About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR

About Us
  Research & Development
  Branded Formulations
  Financial Results
  - Q1 FY21 Conference Call
  - Investor Presentation
  - Disclosure to Stock Exchange
  - Annual Reports
   Biocon's Preparedness For  CoViD-19

 Biocon's Breakthrough Drug Itolizumab

Biocon's Breakthrough Drug Itolizumab

 Annual Report 2020

Annual Report 2020

  - Notice of 42nd Annual General   Meeting
  - Annual Report 2020
  - Biocon Profile
  - CMD Profile
  - Video Gallery

  Biocon Academy



Biocon Limited is a globally recognized, innovation-led organization that is enabling access to high quality, advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high.

We are driven by the belief that the pharmaceuticals industry has a humanitarian responsibility to provide essential drugs to patients who are in need and to do so with the power of innovation. In line with this belief, Biocon has developed and commercialized a differentiated portfolio of novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as, generic formulations in the U.S. and Europe. We are a leading global player for biosimilars and APIs for statins, immunosuppressants and other specialty molecules, with customers in over 120 countries.

Our subsidiary Biocon Biologics is engaged in developing high quality, affordable biosimilars aimed at expanding patient access to a cutting-edge class of therapies across the world. It is uniquely positioned as a fully integrated 'pure play' biosimilars organization globally. Biocon Biologics aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical development with three of these commercialized in developed markets like EU, Australia, U.S. and Japan. Biocon Biologics has a product pipeline of 28 molecules, including 11 partnered with Mylan, several with Sandoz and many being developed independently. A leading global insulins player with over 15 years of experience in addressing the needs of diabetes patients, it has provided over 2 billion doses of recombinant human insulin (rh-insulin) worldwide, thus far. To enable universal access to high quality insulin, it is offering rh-insulin at less than 10 US cents / day for direct procurement by governments in low and middle-income countries.



Expert Panel Discussion on Itolizumab, by Vishal Dahiya, Rajya Sabha TV, July 17, 2020

    Video Credit: Rajya Sabha TV

Biocon Corporate Overview
Stock Update

Company Announcements


Aug 31, 2020 
Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes

July 31, 2020 
Tata Capital Growth Fund to Invest ~USD 30 million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85% Deal Values Biocon Biologics at USD 3.5 Billion.

July 23, 2020 
Biocon Q1FY21 Revenue at Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr

July 21, 2020 
Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins

  Media Coverage  

Aug 07, 2020:
Webinar on "Compassionate Capitalism" with Kiran Mazumdar-Shaw

July 25, 2020:
Biocon Bets Big on Biosimilars, Generics Unit for Fast Growth

July 25, 2020:
Itolizumab to be a great opportunity for Biocon

July 14, 2020:
Initial response to Covid drug Itolizumab 'extremely encouraging', says Biocon

July 14, 2020:
Biocon eyes global markets to supply drug

July 14, 2020:
Itolizumab best used pre-ventilator: Data







Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved